Guidelines on the management of Waldenström macroglobulinaemia.
Johnson
S A
SA
Taunton and Somerset NHS Trust, Taunton, UK.
Birchall
J
J
Luckie
C
C
Oscier
D G
DG
Owen
R G
RG
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D017338:Cladribine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010951:Plasma Exchange; D011379:Prognosis; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000379:methods; D013792:Thalidomide / Q000627:therapeutic use; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D017338:Cladribine; D000069283:Rituximab; D013792:Thalidomide; D014740:Vidarabine; C024352:fludarabine